S&P 500 Technology Sector SEC Filings — March 25, 2026

25-03-2026

Century Communities, Inc. reported strong 2025 financial performance with $4.1B in total revenues, $147.6M net income ($4.86 per diluted share), and a record book value per share of $89.21 (+5% YoY), while delivering 10,792 residential units and returning a record $178.4M to stockholders via dividends and $144M in repurchases despite a challenging environment. Operationally, net new contracts reached 10,326 with a 60,916 lot pipeline, and 94% of deliveries were affordable homes below FHA limits. The proxy seeks approval for director elections, auditor ratification, and say-on-pay, highlighting governance enhancements like reduced executive compensation (e.g., Exec Chairman target STI down 30% from 2024) and board refreshment.

• ·Annual meeting scheduled for May 6, 2026 at 1:00 p.m. MT, Hyatt Regency Denver Tech Center, Denver, CO; record date March 9, 2026.
• ·Net homebuilding debt to net capital ratio: 25.9% as of 2025.
• ·Direct construction costs on starts declined by average $13,000 per home in 2025.
• ·Board governance: 5/7 directors independent (>70%), annual elections, majority vote standard, hedging/pledging prohibitions.
• ·Engaged top stockholders representing 78% of shares in 2025.

25-03-2026

Dyadic International reported 2025 full-year revenue of $3.09 million, down 12% YoY from $3.50 million, primarily due to lower research and development ($0.97M vs $1.61M) and license/milestone revenue ($0.27M vs $1.89M), despite a $1.86 million increase in grant revenue. Net loss widened to $7.36 million or $(0.23) per share from $5.81 million or $(0.20) per share, with operating loss increasing to $7.19 million from $5.90 million, though cash position stood at $8.59 million (down from $9.29 million). The company highlighted progress with commercial launches including AlbuFree™ DX by Proliant, DNase I with Fermbox Bio, and agreements with IBT Bioservices, BRIG Bio, and Inzymes, positioning for future revenue streams.

• ·Research and development revenue: $967,311 in 2025 vs $1,605,220 in 2024.
• ·Cost of research and development revenue: $600,700 in 2025 vs $1,194,624 in 2024.
• ·Earnings call scheduled for March 25, 2026 at 5:00 p.m. ET.
• ·CRISPR/Cas9 non-exclusive license agreement with ERS Genomics signed.
• ·AdaptVac (CEPI-supported): $12.4 million filovirus vaccine program.
• ·European Vaccines Hub (EVH): €170 million EU-backed initiative.

25-03-2026

Texas Community Bancshares, Inc. (TCBS) reported a profitable year in 2025 with net income of $2,842 thousand, reversing a $1,305 thousand loss in 2024, driven by higher net interest income of $13,314 thousand (up 6%) and positive noninterest income of $3,079 thousand versus a $1,903 thousand loss, alongside NIM expansion to 3.26%. However, total assets declined 3% to $429,842 thousand, deposits fell 2% to $327,904 thousand, and nonperforming assets surged 316% to $11,407 thousand or 2.65% of total assets from 0.62%, primarily due to foreclosures adding $9,271 thousand in other real estate owned. Loans grew 3% to $303,205 thousand net, with commercial real estate increasing to $61.5 million (20.1% of loans) from $56.1 million, while construction and land loans declined to $48.4 million (15.8%) from $54.1 million.

• ·Nonaccrual loans decreased to $2,014 thousand from $2,125 thousand.
• ·Provision for credit losses increased to $831 thousand from $158 thousand.
• ·Total capital to risk-weighted assets improved to 16.67% from 15.60%.
• ·Net charge-offs to average loans were -0.17% in 2025 versus -0.05% in 2024.
• ·Premises and equipment net book value: Main office $1,668 thousand; Lindale branch $4,062 thousand.

25-03-2026

Hagop Kozanian, Senior Vice President of Texas Instruments Incorporated (TXN), announced his intention to retire effective August 31, 2026, as disclosed in an 8-K filing on March 25, 2026. The filing was signed by Katharine Kane, Senior Vice President, Secretary and General Counsel. No information on a successor or any financial impact was provided.

• ·Company headquarters: 12500 TI Boulevard, Dallas, Texas 75243
• ·Registrant’s telephone number: (214) 479-3773
• ·Common Stock, par value $1.00, trading symbol TXN on The Nasdaq Global Select Market

25-03-2026

Bristol-Myers Squibb Company's DEF 14A Proxy Statement, filed March 25, 2026, details the virtual 2026 Annual Meeting of Shareholders on May 5, 2026, at 10:00 a.m. EDT, with record date March 12, 2026, to elect 11 Board directors, conduct an advisory vote on Named Executive Officer compensation, approve the 2026 Stock Award and Incentive Plan, ratify Deloitte & Touche LLP as independent auditors, and consider a shareholder proposal. The filing references XBRL-tagged compensation disclosures for Principal Executive Officer (Dr. Giovanni Caforio through 2023, transitioning to Dr. Chris Boerner from 2023 onward) and Non-PEO NEOs across fiscal years 2021-2025, including equity awards, pension adjustments, and fair value changes, though specific amounts are not provided in the excerpt.

• ·Virtual meeting platform: www.virtualshareholdermeeting.com/BMY2026; log in from 9:50 a.m. EDT
• ·Voting methods: www.proxyvote.com, toll-free (800) 690-6903, or mail proxy card
• ·Shareholders of record as of March 12, 2026 entitled to vote common and preferred stock

25-03-2026

Planet 13 Holdings Inc. listed 16 wholly-owned subsidiaries focused on cannabis operations including license holding, retail sales, cultivation, processing, and related activities in Nevada, California, Illinois, and Florida. The filing outlines extensive risk factors, including federal cannabis prohibition, regulatory compliance challenges, competition, operational dependencies, and lack of profitability assurances, with no positive financial performance metrics highlighted. It details the VidaCann acquisition with total consideration of $50,755,443, comprising $4,000,000 cash, 81,872,252 common shares valued at $42,123,314, and a $4,632,129 note payable.

• ·Two subsidiaries listed as inactive: ORB13T LLC and Club One Three, LLC.
• ·Compliance measures include inventory tracking to prevent diversion and policies against distribution to minors or criminal enterprises.
• ·Reliance on Co-CEOs for significant shareholder influence.

25-03-2026

Canadian Pacific Kansas City Limited filed its 2026 Notice of Annual Meeting of Shareholders and 2026 Management Proxy Circular (dated March 10, 2026) with Canadian securities regulatory authorities on March 25, 2026, and attached it as Exhibit 99.1 to this Form 8-K. The company also filed the Notice of Availability of Materials for the 2026 Annual Meeting (Exhibit 99.2) and issued a press release announcing these filings (Exhibit 99.3). This filing satisfies U.S. reporting requirements as a foreign private issuer using domestic forms.

• ·Principal executive offices: 7550 Ogden Dale Road S.E., Calgary, Alberta, Canada, T2C 4X9
• ·Securities registered: Common Shares (CP on NYSE and TSX); Perpetual 4% Consolidated Debenture Stock (CP40 on NYSE, BC87 on London Stock Exchange)

25-03-2026

Planet Fitness, Inc. (PLNT) filed a DEFA14A Definitive Additional Materials proxy statement on March 25, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing includes a reference to 'a2026proxynotice.htm' indicating additional proxy solicitation materials for 2026. No fee was required for this submission.

25-03-2026

Dime Community Bancshares, Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.25 per common share, payable on April 24, 2026, to holders of record as of April 17, 2026. The announcement was made on March 25, 2026, via a press release furnished as Exhibit 99.1.

• ·Press release dated March 25, 2026, attached as Exhibit 99.1 and furnished, not filed
• ·Securities registered on Nasdaq Stock Market, LLC

25-03-2026

Cadence Design Systems Inc.'s DEF 14A proxy statement, filed March 25, 2026, highlights robust corporate governance including an independent board chair, ten of eleven independent directors, annual board evaluations, stock ownership guidelines, and strong stockholder rights such as majority voting and proxy access. Key proposals for the annual meeting include election of directors, approval of the amendment to the Omnibus Equity Incentive Plan, advisory resolution on named executive officer compensation, and ratification of the independent auditors. The filing includes pay versus performance disclosures with equity award details for Principal Executive Officer Dr. Devgan and other NEOs across fiscal years 2021-2025, alongside Compensation Discussion and Analysis.

• ·Stock Ownership Guidelines require CEO to hold shares worth 3X annual base salary and other executive officers 1X annual base salary, within five years of appointment.
• ·Board limits on directors serving on other public company boards, with stricter limits for executive officers.
• ·Corporate governance documents available at www.cadence.com and upon request to Corporate Secretary.

25-03-2026

Acadia Healthcare Company, Inc. (ACHC) filed a DEFA14A Definitive Additional Materials proxy statement on March 25, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No specific financial data, proposals, or other substantive details are included in the provided filing header.

• ·Filing Type: DEFA14A (Schedule 14A Information)
• ·Filed by the Registrant

25-03-2026

Lafayette Square USA, Inc. filed a Form 8-K on March 25, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), attaching Exhibit 99.1. No specific financial metrics, period comparisons, or performance details are provided in the available content.

• ·Filing Type: 8-K
• ·Items Reported: 2.02, 9.01
• ·Subcategory: Unregistered Securities Sale
• ·Exhibit: 99.1 attached

25-03-2026

On March 25, 2026, Micron Technology, Inc. commenced cash tender offers to purchase any and all of its outstanding senior notes, including 5.300% Senior Notes due 2031, 5.650% Senior Notes due 2032, 5.875% Senior Notes due 2033 (two series), 5.800% Senior Notes due 2035, and 6.050% Senior Notes due 2035. The press release detailing the offers is attached as Exhibit 99.1.

• ·Common Stock: par value $0.10 per share, trading symbol MU on Nasdaq Global Select Market
• ·Principal executive offices: 8000 South Federal Way, Boise, Idaho 83716-9632
• ·Registrant’s telephone number: (208) 368-4000

25-03-2026

On March 23, 2026, Muzinich Corporate Lending Income Fund, Inc. announced a leadership transition effective April 1, 2026, with CEO Jeffrey Youle and CFO/Treasurer Paul Fehre stepping down from their executive roles but continuing as Board members and in other capacities at Muzinich & Co., Inc., with no disagreements noted. The Board appointed Cheryl Rivkin as new CEO, Jens Ernberg as President, Rocco DelGuercio as new CFO/Treasurer, and Susan Cohen as Secretary. No related party transactions or arrangements were disclosed.

• ·Former CEO Jeffrey Youle will serve as Senior Adviser at Muzinich; former CFO Paul Fehre as Chief Operating Officer at Muzinich.
• ·Cheryl Rivkin, 56, joined Muzinich in 2003; Jens Ernberg, 56, joined in 2025; Rocco DelGuercio, 62, joined in November 2025; Susan Cohen, 42, joined in 2017.

25-03-2026

Muzinich BDC, Inc. announced on March 23, 2026, a leadership transition effective April 1, 2026, with President and CEO Jeffrey Youle and CFO and Treasurer Paul Fehre stepping down from their executive roles but remaining on the Board; no disagreements were noted. The Board appointed Cheryl Rivkin as new CEO, Jens Ernberg as President, Rocco DelGuercio as CFO and Treasurer, and Susan Cohen as Secretary. All new executives are currently affiliated with Muzinich & Co., Inc.

• ·Departing executives expressed no disagreement on Company operations, policies, or practices.
• ·No arrangements or understandings between new appointees and the Company or other entities requiring disclosure under Item 404(a) of Regulation S-K.
• ·New appointees have prior experience at firms including Capital Dynamics, Credit Suisse, and Investcorp.

25-03-2026

Adobe Inc. filed a supplement to its definitive proxy statement for the 2026 Annual Meeting of Stockholders, disclosing that CEO Shantanu Narayen notified the company on March 9, 2026, of his decision to transition from his CEO role, with Adobe conducting a search for a successor. Mr. Narayen will remain CEO until a successor is appointed and continue as Chair of the Board of Directors. The supplement confirms that voting matters remain unchanged, and previously submitted proxies are valid unless revoked.

• ·Annual Meeting to be held virtually on April 15, 2026 at 9:00 a.m. Pacific Time.
• ·Original Proxy Statement filed with SEC on February 27, 2026.
• ·Stockholders who have already voted do not need to take action unless they wish to change their vote.